3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Temozolomide
15
Radiotherapy
11
Everolimus
6
Bevacizumab
6
Irinotecan
5
Cyclophosphamide
5
ribociclib
4
Radiation
4
Panobinostat
4
TIC10 compound
3
Specimen Handling
3
Re-Irradiation
3
Etoposide
3
Dasatinib
3
pembrolizumab
2
nimotuzumab
2
abemaciclib
2
Vorinostat
2
Valproic Acid
2
Topotecan
2
Nivolumab
2
Mebendazole
2
Magnetic Resonance Spectroscopy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Gemcitabine
2
GDC-0084
2
Erlotinib Hydrochloride
2
Diphtheria-Tetanus Vaccine
2
Cilengitide
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Diffuse Intrinsic Pontine Glioma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled